Modality
mAb
MOA
C5i
Target
KRASG12D
Pathway
Autophagy
Alzheimer'sALL
Development Pipeline
Preclinical
Jun 2017
→ Sep 2028
PreclinicalCurrent
NCT03633103
1,770 pts·Alzheimer's
2017-06→2028-09·Completed
NCT08956140
1,398 pts·Alzheimer's
2019-03→2026-07·Not yet recruiting
3,168 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-234mo awayInterim· Alzheimer's
2028-09-102.4y awayInterim· Alzheimer's
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Complet…
Preclinical
Not yet…
Catalysts
Interim
2026-07-23 · 4mo away
Alzheimer's
Interim
2028-09-10 · 2.4y away
Alzheimer's
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03633103 | Preclinical | Alzheimer's | Completed | 1770 | ORR |
| NCT08956140 | Preclinical | Alzheimer's | Not yet recr... | 1398 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 |